Palmarumycin CP 18 , isolated from an extract of the fermentation broth and mycelium of the Panamanian endophytic fungus Edenia sp., was previously reported with strong and specific activity against Leishmania donovani. Here we report that when the same strain was cultured on different solid media -Harrold Agar, Leonian Agar, Potato dextrose Agar (PDA), Corn Meal Agar, Honey Peptone Agar, and eight vegetables (V8) Agar -in order to determine the optimal conditions for isolation of palmarumycin CP 18 , no signal for this compound was observed in any of the 1 H NMR spectra of fractions obtained from these extracts. However, one extract, prepared from the fungal culture in PDA contained significant amounts of CJ-12,372, a possible biosynthetic precursor of palmarumycin CP 18 . Edenia sp. was cultivated on a large scale on PDA and CJ-12,372 was converted to palmarumycin CP 18 by oxidation of its phydroquinone moiety with DDQ in dioxane. Palmarumycin CP 18 showed anti-leishmanial activity against L. donovani in a macrophage/amastigote model, with IC 50 values of 23.5 µM.
The protozoan Leishmania causes a variety of clinical diseases that afflict 12 million people worldwide [1] . Reducing the lethality and morbidity of leishmaniasis relies primarily on chemotherapeutic treatment. Currently, the available drugs have significant shortcomings, including high toxicity, long therapeutic regimens, parenteral administration and high cost, making new strategies for the treatment of leishmaniasis greatly needed [2] .
Among the different strategies for the discovery of new compounds is the use of biodiversity for bioactive natural products extracted from plants, fungi and other organisms [3] . Many groups of products extracted from nature have established antiparasitic properties with great effectiveness [4] . For the treatment of leishmaniasis, experimental in vitro and in vivo studies have tested natural compounds from different species, obtaining varying levels of success and revealing substances that might be employed in the future treatment of this disease [5] [6] [7] [8] [9] .
Bioassay-directed fractionation of a crude extract from the fermentation of the fungus Edenia sp., strain F0755, in malt extract broth, led to the isolation of five spirodioxynaphthalenes. One of them, palmarumycin CP 18 , showed significant inhibition of growth of Leishmania donovani (the causative agent of leishmaniasis) in the amastigote form (IC 50 = 0.62 µM) and a weak cytotoxicity to Vero cells (IC 50 = 152 µM) [10, 11] . The spirodioxynaphthalenes have interesting structures and a variety of biological activities such as antitumor, antibacterial, antifungal, antileishmanial, and enzymeinhibitory, and are of great interest as potent lead compounds for medicinal chemistry [12, 13] . In this paper we describe a new large-scale method to obtain palmarumycin CP 18 by oxidation of the p-hydroquinone moiety of CJ-12,372 [14] , a known precursor molecule isolated from fermentation on PDA of the Panamanian endophytic fungus Edenia sp. The leishmanicidal activity of No 1 H NMR signals of palmarumycin CP 18 were observed in any of the fractions obtained from the fermentation of Edenia sp. in Harrold Agar, Leonian Agar, Potato dextrose Agar (PDA), Corn Meal Agar, Honey Peptone Agar, and V8 Agar. However, a large amount of compound CJ-12,372 (possible a biosynthetic precursor of palmarumycin CP 18 ) was identified in PDA culture. The highest production of CJ-12,372 was after 30 days of growth of Edenia sp cultured in PDA. Figure 1 shows the activity of palmarumycin CP 18 at different concentrations in murine macrophages infected with L. donovani. Palmarumycin CP 18 at 25 µg/mL (74.8 M) promoted disruption of murine macrophages. However, this concentration was below the IC 90 value estimated through statistical analysis in the MiniTab program (35.8 M). Palmarumycin CP 18 was toxic to the Vero cell line at 152 M [10] . The IC 50 and IC 90 values determined for palmarumycin CP 18 for murine macrophages infected with L. donovani were 7.8 g/mL (or 23.5 M) and 11.9 g/mL (or 35.8 M) (Table 1 ). In a previous study, a lower IC 50 value (0.62 M) was obtained when palmarumycin CP 18 was assessed by the axenic amastigote assay [10] . The differences observed can be explained by the use of different evaluation techniques. Variations in IC 50 values determined by the use of different techniques for different Leishmania species were observed previously [15] . Edenia sp is an interesting source of spirodioxynaphthalenes. They have been reported with a wide range of different biological activities, and with interesting targets to test novel synthetic strategies and asymmetric reactions of novel chiral reagents. This strain, cultured in PDA, produces a high amount of the known DNA gyrase inhibitor, CJ-12,372. The synthetic compound palmarumycin CP 18 , obtained by oxidation of the hydroquinone moiety of CJ-12,372, did not show the same activity reported previously [10] . One of the reasons could be the bioassay procedure, as the bioactivity of palmarumycin CP 18 against L. donovani reported previously was obtained with axenic amastigotes; assays that require less drug concentration than the macrophage/amastigote model that we used.
Experimental

General experimental procedures:
Optical rotations were measured with a Rudolf Research Analytical Autopol III 6971 automatic polarimeter. NMR spectra were recorded in CDCl 3 and DMSO-d6 on a Bruker spectrometer with standard pulse sequences operating at 300 MHz in 1 H NMR and 75 MHz in 13 C NMR using TMS as an internal shift reference. Spectra were referenced to residual solvent signals with resonances at δ H/C 7.26/77.0 for CDCl 3 and δ H/C 2.50/39.5 for DMSO-d6. LC-MS were recorded on a Waters Acquity UPLC with PDA, ELS and SQ MS detectors. The column was an Acquity UPLC BEH C 18 (1.7 μm, 2.1 x 50 mm). Reverse phase HPLC was performed on a Waters 600 model system with a photodiode array UV detector 2996, a preparative RP 18 -HPLC column (SymmetryPrep™ Waters C 18 7 μm, 19-300 mm column, Part No. WAT066245), and a semi-preparative RP 18 -HPLC (XTerra Prep RP18, 10 µm, 10 x 250 mm column, Part. No. 186001028). For vacuum liquid chromatography, an octadecyl-functionalized silica gel column (Sigma-Aldrich) was used, and for CC, a silica gel column (200-400 mesh, Sigma-Aldrich). All solvents were HPLC grade and were used without further purifications.
Fungal material:
The isolation of the endophytic fungus Edenia sp. was described earlier [10] .
Culture of Edenia sp: Edenia sp., strain F0755, was cultivated on a small scale using 6 different solid media, Harrold Agar, Leonian Agar, Potato Dextrose Agar (PDA), Corn Meal Agar, Honey Peptone Agar, and eight vegetables Agar (Figure 2 ). Cultures on Harrold Agar, Leonian Agar and PDA were incubated for 24 days and cultures on Corn Meal Agar, Honey Peptone Agar and V8 agar for 14 days, all at room temperature.
The media composition for 1 L: Harrold Agar (20 g of malt extract, 400 g of sucrose, 5 g of yeast extract, 20 g of agar); Leonian Agar (6.25 g of lactose, 0.625 g of peptone, 6.25 g of malt extract, 1.25 g of KH 2 PO 4 , 0.625 g of MgSO 4 , 20 g of agar); PDA (24 g of PDB-Difco and 15 g of agar); Corn Meal Agar (60 g of corn meal, and 15 g of agar); Honey Peptone Agar (60 g of honey, 10 g of peptone, 20 g of agar); and eight vegetables Agar (250 mL of V-8 juice, 5.625 g of CaCO 3 , 18.75 g of agar). Preparation and analysis of extracts: Each culture was lyophilized and extracted with EtOAc (4 x 500 mL). The organic solutions were concentrated under vacuum to give one extract from each culture ( Table 2) . Each extract was fractionated with different chromatography techniques (VLC, HPLC-RP 18 ), and all fractions were analyzed by 1 H NMR to identified the signals of palmarumycin CP 18 . Isolation and optimization of production of CJ-12,372: Edenia sp. was cultivated in PDA for 8, 15, 20 and 30 days at room temperature ( Table 3 ). The EtOAc extract from each group of cultures was fractionated by reverse phase HPLC. The t R of compound CJ-12,372 was 10.8 min using an isocratic flow of CH 3 CN-H 2 O 8:2 at 7 mL/min and a preparative RP-HPLC column (SymmetryPrep™ Waters C 18 7μm, 19-300 mm column, Part No. WAT066245). The structure was determined based on comparison of its specific rotation, and 1 H and 13 C NMR shifts with previous reports in the literature [14] . Natural Product Communications Vol. 9 (1) 2014 97 temperature for 30 days. The culture was dried by lyophilization and extracted exhaustively with EtOAc (8 x 4 L). The organic solution was concentrated under vacuum to give a dark brown solid (8.8 g), which was subjected to octadecylsilane (500 g). Elution by vacuum liquid chromatography (VLC) with MeOH-H 2 O 6:4, MeOH (100 %) and CHCl 3 (100 %) yielded 3 fractions (F1-F3). 1 H NMR analysis of fraction 1 (F1) (852 mg) revealed a large quantity of compound CJ-12,372. F1 was combined with 800 mg of DDQ in 50 mL of dioxane in a 100 mL beaker and stirred continuously for 24 h (Figure 3 ). The product of this reaction was concentrated under vacuum and the solid obtained was subjected to Si gel (90 g) open CC eluting with 500 mL of C 6 H 14 -CHCl 3 (1:1) ) for 20 min at 1 mL/min The structure was determined based on comparison of its specific rotation, and 1 H and 13 C NMR shifts with literature data [10, 16] . In vitro evaluation of anti-parasitic activity of palmarumycin CP 18 . Parasite and cultivation of promastigotes: L. donovani strain MHOM/ET/1967/HU3 was used throughout the study. The strain was maintained by sucessive passages in golden hamsters (Mesocricetus auratus) and amastigotes were harvested from the spleen of infected animals. Promastigotes of L. donovani were cultured in Schneider's medium supplemented with 20 % heatinactivated fetal bovine serum (FBS) (Gibco, Grand Island, NY, USA) and the antibiotics penicillin (100 U/mL) and streptomycin (100 µg/mL). Parasites were maintained at 26ºC and used at stationary phase of growth to infect macrophages.
Oxidation of the p-hydroquinone moiety of CJ
Amastigote-macrophage assay:
Balb/c mice were injected intraperitoneally with 1.5 mL of a 3% thioglycolate medium (Biobrás, Brazil). After 72 h, the periperitoneal macrophages were harvested and washed with cold RPMI 1640 medium (Sigma Aldrich, USA). The macrophages were then counted, centrifuged at 300g for 7 min at 4ºC and resuspended at a concentration of 4 x 10 5 cells/mL in RPMI-1640 medium without supplementation. Sterile round plastic coverslips (13 mm; Sarstedt, Newton, NC, USA) were placed in each well of 24-well culture plates. In each well, 500 μL of the macrophage solution was allowed to attach to the coverslips for 2 h at 37ºC in 5% CO 2 . Culture medium was then aspired and replaced with 500 μL of fresh RPMI medium supplemented with 10% FBS, penicillin (100 U/mL) and streptomycin (100 μg/mL) at 37ºC for 24 h. After 24 h, a suspension of 3.6 x 10 6 parasites/mL of L. donovani promastigote forms at stationary phase were added to each well in 500 μL of RPMI with a final macrophage to parasite ratio of 1:9. The plates were incubated for 4 h at 37ºC in 5% CO 2 .
The medium was then aspirated to remove free-floating parasites. Fresh RPMI (1 mL) was added containing different palmarumycin CP 18 concentrations (25.0 g/mL or 74.8 M to 0.78 g/mL or 2.3 M). Amphotericin B deoxycholate (AmB) (Anforicin B, Cristália, Brasil -AmB) at 0.2 μg/mL and fresh medium without drug were also added to separate triplicate wells as control. After 72 h incubation at 37ºC in 5% CO 2 , the medium was aspirated and the coverslips were removed, air-dried and glued to microscope slides. Following staining with Giemsa reagent, the cells were counted. The assay results were analyzed if at least 80% of the macrophages in the control wells were infected. Three independent experiments in triplicate were performed for each drug concentration to determine the palmarumycin CP 18 efficacy. The results were presented as the ratio of infection (number of amastigotes/100 macrophages) between the treated and non-treated macrophage cultures and were expressed as inhibitory concentrations of 50% and 90% (IC 50 and IC 90 ) as calculated by linear regression analysis (MiniTab 13.1). The animals used in this study were handled according to local and federal regulations and the research protocols were approved by the Fiocruz Committee on Animal Research (LW-6/13).
